Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases

Clinical Pharmacokinetics

Volumn 53, Issue 2, 2014, Pages 155-164

  Karaźniewicz ŁAda, Marta ^a   Danielak, Dorota ^a   Burchardt, Paweł ^a   Kruszyna, Łukasz ^a   Komosa, Anna ^a   Lesiak, Maciej ^a   Główka, Franciszek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CARBOXYLIC ACID; CLOPIDOGREL; DRUG METABOLITE; THIOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAPILLARY ELECTROPHORESIS; CARDIOVASCULAR DISEASE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOMER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84893270831     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0105-2     Document Type: Article

References (38)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-39.
2. De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008;100:196-203.
3. Karaźniewicz-Łada M, Danielak D, Główka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother. 2012;13:663-83.
4. Taubert D, Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486-501.
5. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50:126-42.
6. Mani H, Toennes SW, Linnemann B, Urbanek DA, Schwonberg J, Kauert GF, Lindhoff-Last E. Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy? Ther Drug Monit. 2008;30:84-9.
7. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9.
8. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-6.
9. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-62.
10. Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon MC, Hurbin F, Sultan E. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost. 2011;105:696-705.
11. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288-95.
12. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-42.
13. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-36.
14. Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59:1304-11.
15. Yousef A-M, Arafat T, Bulatova NR, Al-Zumyli R. Smoking behavior modulates pharmacokinetics of orally administered clopidogrel. J Clin Pharm Ther. 2008;33:439-49.
16. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2008;48:1219-24.
17. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25:25-8.
18. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schömig A, Schömig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004;92:311-6.
19. Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol. 2008;52:1968-77.
20. Heestermans AACM, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schömig E, Verheugt FW, ten Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122:776-81.
21. Deray G, Bagnis C, Brouard R, Necciari J, Leenhardt AF, Raymond F, Baumelou A. Clopidogrel activities in patients with renal function impairment. Clin Drug Investig. 1998;16:319-28.
22. Karaźniewicz-Łada M, Danielak D, Teżyk A, aba C, Główka F. HPLC-MS/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples. J Chromatogr B. 2012;911:105-12.
23. Karaźniewicz-Łada M, Główka F, Oszkinis G. Capillary zone electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies. J Chromatogr B. 2010;878:1013-8.
24. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA, Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-33.
25. Delavenne X, Basset T, Zufferey P, Malouk N, Laporte S, Mismetti P. Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. J Sep Sci. 2010;33:1968-72.
26. Peer CJ, Spencer SD, VanDenBerg DA, Pacanowski MA, Horenstein RB, Figg WD. A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. J Chromatogr B. 2012;880:132-9.
27. Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010;32:161-70.
28. El Ahmady O, Ibrahim M, Hussein AM, Bustami RT. Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers. Int J Clin Pharmacol Ther. 2009;47:780-4.
29. Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, LaCreta F, Cheng S, Sultan E. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study in healthy men. J Clin Pharmacol. 2012;52:1506-15.
30. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol. 2007;2:93-109.
31. Sibbing D, Taubert D, Schomig A, Kastrati A, Von Beckerath N. Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost. 2008;6:1230-2.
32. Furlong MT, Savant I, Yuan M, Scott L, Mylott W, Mariannino T, Kadiyala P, Roongta V, Arnold ME. A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B. 2013;926:36-41.
33. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, Herdeg C, Gawaz M. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost. 2008;6:54-61.
34. Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61:872-9.
35. Bonello L, Armero S, Ait Mokhtar O, Mancicni J, Aldebert P, Saut N, Bonello N, Barragan P, Arques S, Giacomoni MP, Bonello-Burignat C, Bartholomei MN, Dignat-George F, Camoin-Jau L, Paganelli F. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C192 loss of function polymorphism. J Am Coll Cardiol. 2010;56:1630-6.
36. Mega J, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306:2221-8.
37. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419-30.
38. Sprague DA, Ensom MH. Limited-sampling strategies for anti-infective agents: systematic review. Can J Hosp Pharm. 2009;62:392-401.